Imdelltra (tarlatamab-dlle) / Amgen 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imdelltra (tarlatamab-dlle) / Amgen
NCT06064500: Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

Available
3b
Japan, US, RoW
Tarlatamab, AMG 757
Amgen
Small Cell Lung Cancer
 
 
DeLLphi-305, NCT06211036: Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Recruiting
3
550
Europe, Japan, US, RoW
Tarlatamab, AMG 757, Durvalumab
Amgen
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
09/27
09/28
DeLLphi-304, NCT05740566: Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

Active, not recruiting
3
509
Europe, Canada, Japan, US, RoW
Tarlatamab, AMG 757, Lurbinectedin, Topotecan, Amrubicin
Amgen
Small Cell Lung Cancer (SCLC)
07/27
07/27
DeLLphi-306, NCT06117774: Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

Recruiting
3
400
Europe, Japan, US, RoW
Tarlatamab, AMG 757, Placebo
Amgen
Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
10/29
10/29
DeLLphi-301, NCT05060016 / 2021-002566-40: A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

Active, not recruiting
2
222
Europe, Japan, US, RoW
Tarlatamab
Amgen
Relapsed/Refractory Small Cell Lung Cancer
10/25
10/26
DeLLphi-307, NCT06502977: Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment

Recruiting
2
30
RoW
Tarlatamab, AMG 757, IMDELLTRA™
Amgen
Advanced Small Cell Lung Cancer
09/25
09/26
NCT04885998: AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)

Active, not recruiting
1b
23
Europe, Japan, US, RoW
Tarlatamab, AMG 757, AMG 404
Amgen
Small Cell Lung Cancer
07/23
01/25
DeLLpro-300, NCT04702737: A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

Active, not recruiting
1
41
Europe, Japan, US, RoW
Tarlatamab, AMG 757
Amgen
Neuroendocrine Prostate Cancer
08/25
08/25
DeLLphi-308, NCT06598306: Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer

Not yet recruiting
1
100
US, RoW
Tarlatamab, AMG 757, Imdelltra
Amgen
Extensive Stage Small Cell Lung Cancer
04/27
05/28
DeLLphi-300, NCT03319940: Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

Active, not recruiting
1
269
Europe, Japan, US, RoW
Tarlatamab, Pembrolizumab, CRS Mitigation Strategies
Amgen
Small Cell Lung Carcinoma
10/24
10/25
DeLLphi-303, NCT05361395: First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Active, not recruiting
1
184
Europe, Canada, Japan, US, RoW
Tarlatamab, AMG 757, Carboplatin, Etoposide, Atezolizumab, Tecentriq, Durvalumab
Amgen
Extensive Stage Small Cell Lung Cancer
08/28
08/28

Download Options